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Summary: Bone morphogenetic protein 2 (BMP-2) is a potent inducer of osteoblast-mediated bone formation and is used in orthopaedic
applications in humans. This study was performed to evaluate (1) recombinant human BMP-2 (rhBMP-2) in clinical cases of subchondral
cystic lesion (SCL) in horses and  (2) the osteoinductive effects of rhBMP-2 treatment in vitro on primary equine osteoblasts. Three horses
with SCLs of the proximal interphalangeal (PIP) joint and associated lameness were treated by transcortical debridement and implantation
of a collagen sponge containing rhBMP-2. In the in vitro studies, equine osteoblasts were cultured with rhBMP-2 to assess the effects of
rhBMP-2 on their differentiation and mineralization. The treatment of SCLs with rhBMP-2 was well tolerated by all the horses, and impro-
vements in subchondral bone radiographic appearance and lameness score were evident between 7 and 10 months post-surgery. Equine
osteoblasts treated with rhBMP-2 demonstrated enhanced mineralization as evidenced by increases in Alizarin Red S staining. This was
accompanied by significant increases in alkaline phosphatase (ALP) expression and activity, and a significant decrease in secreted osteocal-
cin levels. In conclusion rhBMP-2 can be used to assist in subchondral bone repair in horses, and we provide in vitro evidence to suggest
that its influence on bone formation is mediated through enhanced osteoblast activity. 
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Introduction 
Subchondral cystic lesions (SCLs) occur in horses as soft tis-
sue-filled defects in subchondral bone. Although their origin
is unclear, SCLs often pose a substantial problem because
they stimulate inflammation, are covered with degenerated
cartilage, and often result in lameness (von Rechenberg et al.
2000). SCLs are found in many locations, most commonly
the medial femoral condyle, followed by the phalanges, car-
pal bones, 3rd metacarpal and metatarsal bones, tibia,
radius, talus, sesamoid bones, and humerus (von Rechenberg
et al. 1998). Surgical debridement is the standard surgical
procedure used to treat equine SCLs and involves an arthro-
scopic or transcortical approach for curettage of the cyst con-
tent and cyst lining (Fürst et al. 1997, Story and Bramlage
2004). This may be accompanied by filling the defect with
agents designed to enhance bone formation, including osteo-
inductive proteins. Parathyroid hormone peptide (PTH1-34) in
fibrin hydrogel administered locally into SCLs led to a 78.6%
recovery of the treated horses (Jackson et al. 2012). Although
the exact mechanism of the anabolic effect with PTH is not
clear, its main function is attributed to stimulating osteoblast
proliferation (Rubin and Bilezikian 2003). Treatment of equi-
ne SCLs using insulin-like growth factor (IGF)-1 in combina-
tion with allogeneic chondrocytes led to improved healing in
the short-term (8 weeks) and long-term (8 months) follow-up
with a successful outcome in 80% of horses over 3-years-of-
age, even in the presence of joint degeneration (Ortved et al.
2012). It has been suggested that horses older than three
years tend to be more refractory to the previously described
treatments; Smith et al. (2005) found that only 35% of horses
older than 3 years became sound after surgical debridement
of an SCL in the medial femoral condyle.
More recently, several studies examined the potential benefi-
cial effects of bone morphogenetic protein (BMP)-2 in the
repair of equine osteochondral defects (Seo et al. 2013, Seo
et al. 2015, Tsuzuki et al. 2013). BMP-2 is a member of the
BMP family, and is predominantly synthesized by osteoblasts
(Smith et al. 2008). Due to its osteoinductive effects (Deve-
scovi et al. 2008), it is approved as an alternative for cancel-
lous bone grafts in humans in special indications (Govender
et al. 2002, Mont et al. 2004). Previous studies demonstrated
that recombinant human BMP-2 (rhBMP-2) loaded scaffolds
accelerated bone regeneration in equine bone defect models
(Perrier et al. 2008, Seo et al. 2014). Gelatin b-tricalcium
phosphate (b-TCP) sponges loaded with rhBMP-2 also enhan-
ced healing of osteochondral defects in horses (Seo et al.
2013, Seo et al. 2015, Tsuzuki et al. 2013). However, as
rhBMP-2 was administered in combination with multipotent
stromal cells (MSCs) and platelet rich plasma (PRP), its actual
contribution to osteochondral repair in these models remains
unclear. Moreover, although the effect of human BMP-2 on
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the osteogenic differentiation of equine bone marrow-derived
MSCs (BMSCs) was described (Carpenter et al. 2010, Glynn
et al. 2013), its effects on equine osteoblasts has yet to be
determined. 
The aim of the present study was to evaluate the clinical out-
come of three equine cases with SCLs following combined
treatment with debridement and collagen sponges containing
rhBMP-2. Furthermore, in vitro studies were undertaken to
assess the effects of rhBMP-2 on the differentiation of equine
osteoblasts and on induction of mineralization.
Material and methods
Recombinant human BMP-2 (rhBMP-2) was purchased as part
of the InductOs kita and used in accordance with the manu-
facturer’s instruction. For in vitro studies, reconstituted rhBMP-
2 was added directly to culture medium at final concentra-
tions of 10, 50, 100 or 200ng/ml. For treatment of equine
SCLs, rhBMP-2 (0.5mg/ml) was evenly applied to a 1cm2
bovine Type I absorbable collagen sponge (ACS) for at least
15 minutes. Up to two sponges were used per defect depen-
ding on the size of the SCL.
Surgical treatment of equine SCLs
Horses included in the study were referred to the Clinic for
Equine Surgery, University of Zurich, between January 2014
and December 2015 because of a forelimb lameness attribu-
table to an SCL in the proximal interphalangeal (PIP) joint (eit-
her located distally in the proximal phalanx (P1) or proximally
in the middle phalanx (P2)). Diagnosis was performed by dia-
gnostic anaesthesia and digital radiographyb. Cases of SCLs
and concomitant fissures, treated with additional cortex
screws, were excluded from the study. In all cases, computed
tomography (CT) was performed under general anaesthesia
in lateral recumbency using a 40-slice helical CT scannerc to
confirm the diagnosis and guide the surgical debridement.
After native CT, the surgical area was aseptically prepared
and surgically draped. A 3.2-mm hole was first drilled trans-
cortically into the cyst, in a predetermined direction and
depth. Then the hole enlarged to 4.5 or 5.5mm. Arthrosco-
pic, thin curettes were used to remove all content and lining
of the cyst, and the cavity flushed with lactated Ringer’s solu-
tion. Pre-soaked collagen sponges containing rhBMP-2
(InductOs)a were then inserted into the cavity and the skin
routinely closed. Phenylbutazone (2.2mg/kg sid)d was admi-
nistered orally for the first 4–6 days, and horses were confi-
ned to box rest for 30 days. Thereafter, horses were turned
out into paddocks (6m2) for up to 4 months before being
allowed to resume normal activities. Complete lameness exa-
mination and radiography of the surgical site were performed
between 7 and 10 months after surgery.
Isolation and culture of equine osteoblasts
Cancellous bone was collected aseptically from the 3rd meta-
carpal bones of 5 healthy, Warmblood horses (5–12-years of
age) slaughtered for reasons unrelated to this study. Equine
osteoblasts were harvested from bone explants using a com-
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bination of enzymatic digestion and outgrowth as previously
described (McCarthy et al. 1988). Bone explants were then
transferred to sterile culture dishes and incubated in normal
growth medium consisting of Dulbecco’s modified eagle
medium (DMEM)e supplemented with 10% foetal bovine
serum (FBS)e, 1% penicillin/streptomycine, 0.3mg/ml Fungi-
zonee and 50mg/ml ascorbic acidf at 37°C/5% CO2. Oste-
oblast differentiation was induced using osteogenic medium
(OM) consisting of alpha-minimum essential medium (MEM)f,
10% FBSe, 1% penicillin/streptomycine, 50µM ascorbic acidf,
10mM b-glycerophosphatef and 100 nM dexamethasonef.
Cells were also incubated in osteogenic medium devoid of
either dexamethasone (OM-D), or in non-osteogenetic
medium, devoid of both dexamethasone and b-glycerophos-
phate (OM-D/BG). The latter were the control cells. Where
stated, rhBMP-2 was included at the indicated concentrations. 
Assessment of osteoblast differentiation and mineralization 
Mineralization was assessed at 10 and 12 days post-osteoge-
nic induction using Alizarin Red Sf staining as previously des-
cribed (Cheng et al. 2003). ALP activity and secreted oste-
ocalcin were measured in cell culture supernatants at selected
time points using enzyme-linked immunosorbent assays (ELI-
SAs) specific for bone-specific ALP (BAP EIA Kit)g and intact
osteocalcin (Osteocalcin EIA Kit)g. Gene expression levels of
COL1A2, RUNX2 and ALP were measured in cells at 2 and 5
days post-osteogenic induction using reverse transcription
quantitative polymerase chain reaction (RT-qPCR) as pre-
viously described (Theiss et al. 2015). Gene expression levels
of COL1A2 and RUNX2 were determined using TaqMan
Gene Expression Assayse. Ec03469522_m1 (COL1A2) and
Ec03469742_m1 (RUNX2) and values normalized to
GAPDH (Ec03210916_gH). ALP expression was determined
by SYBR Greene RT-qPCR (Sun et al. 2015), using the follo-
wing primer pair; forward 5’–GACATGACCTCCCAGGAA-
GA-3’ and reverse 5’-GCAGTCAAGGGCTTCTTGTC–3’.
Values were normalized to GAPDH (forward: 5’–ATCACTGC-
CACCCAGAAGAC-3’; reverse: 5’-GTCAGCTTCCCATT-
CAGCCTC-3’). All data were expressed as fold change as
compared to cells incubated in non-osteogenic medium
(control) at day 2 or day 5 using the comparative CT method. 
Statistical Analysis
All statistical analyses were performed using SPSS 23.0h.
Parametric analysis of normally distributed data was perfor-
med using one-way analysis of variance (ANOVA) followed
by Tukey’s post-hoc test. In all cases, a p-value of <0.05 was
considered statistically significant, and all data were expres-
sed as mean±standard deviation (S.D.).
Results
Treatment of SCLs with rhBMP-2
Three horses with a total of 5 SCLs (2 horses affected bilater-
ally) met the inclusion criteria. The first horse was a 2.5-year-
old mare with intermittent lameness (grade 2/5, AAEP) (Kee-
gan et al. 2010) of the right forelimb, which was abolished
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after a low palmar digital nerve block. On x-ray, an SCL was
visible in the distal proximal phalanx (P1) of the right forelimb
(Figure 1A). CT imaging confirmed a SCL with peripheral
sclerosis and periosteal reactions in the medial condyle of the
distal P1 close to the PIP joint (Figure 1B). The cyst was then
debrided and filled with InductOs (1mg rhBMP-2), and radio-
graphic analysis performed 2 days later (Figure 1C). At 9
months after surgery, the horse showed no signs of lameness,
and radiographic examination confirmed the defect was less
radiolucent and less delineated, suggesting progressive bone
formation (Figure 1D). At 18 months after surgery, the horse
still remained free of lameness and was regularly being used
as pleasure horse.
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The second horse was a 2.5-year-old stallion with moderate
lameness (grade 3/5) of the left forelimb since several
weeks. The lameness was abolished after a palmar abaxial
sesamoid block of the affected limb. On radiography, a lar-
ge SCL was visible in the middle phalanx (P2) of the left fore-
limb, near the PIP joint (Figure 2A). Furthermore, a smaller
defect was suspected in the medial condyle of P1 of the con-
tralateral limb (Figure 2E). CT examination confirmed the
SCLs on both limbs (Figures 2B and F). Both SCLs were
debrided and filled with InductOs, (left defect received 2 mg
rhBMP-2 and the right SCL received 1 mg rhBMP-2) and
radiographs of both defects were acquired 2 days after sur-
gery (Figures 2C and G). At 10 months, the clinical exami-
Fig. 1 (A) Dorsopalmar radiographic view of the right PIP joint of Case 1. A SCL is visible in the medial condyle of the distal P1 as an oval
and smooth defined radiolucent area (black arrow). Irregular periosteal reactions are visible on the medial distal P1 in the area of the origin of
the medial collateral ligament of the PIP joint (white arrow). On dorsal plane CT image (B), a round SCL with peripheral sclerosis (black arrow)
as well as the periosteal reactions (white arrow) are visible. (C) Dorsopalmar radiographic view of the right PIP joint 2 days after surgery. The
drill entry is indicated with an arrow. (D) Radiographic view at 9 months after surgery. A progressive filling of the lesion is evident close to the
joint (black arrow) and the periosteal reactions are smooth (white arrows). 
Fig. 2 Dorsopalmar radiographic views of the PIP joint of both forelimbs of Case 2. On the left side, a large SCL is visible sagittal in the
proximal P2, surrounded by a sclerotic rim (A); On the right side, multiple smaller radiolucent areas are visible parasagittal medial, in the distal
P1, in close proximity to the PIP joint (E).  Dorsal plane CT images confirmed a large SCL on the left side (arrow) (B) and a smaller, irregular
one on the right side (arrow) (F). The drill canal (arrows) is visible on the dorsopalmar radiographic views of the left (C) and right (G) PIP joint
2 days after debridement. (D, H) Same radiographic views 10 months after surgery, showing progressive filling of both defects (arrows).
A B C D
A B C D
E F G H
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nation showed no lameness, and radiographic examination
showed a progressive filling of the defects in both the left
(Figure 2D) and right (Figure 2H) limbs. At 15 months after
surgery, the horse still remained free of lameness and was
regularly being used for dressage. 
The third horse was a 5-month-old filly with moderate, acute
lameness (grade 3/5) of the right forelimb, which was
abolished after a palmar abaxial sesamoid block. On radio-
graphy, an ill-defined radiolucent region was visible in the
distal P1 of the right forelimb (Figure 3A), and a smaller one
on the distal medial P1 of the left side (Figure 3E). CT exa-
mination confirmed a round SCL on the right P1 (Figure 3B)
and a smaller, irregular one on the left P1 (Figure 3F). Both
SCLs were debrided and filled with InductOs (1mg rhBMP-2
each) and control examinations performed two days after
surgery (Figures 3C and G). Radiographic examination 7
months after surgery showed a progressive filling of the both
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defects (Figures 3D and H), and the filly was still free of
lameness at 13 months post-surgery. 
Effect of rhBMP-2 on equine osteoblast differentiation 
Primary equine osteoblasts were incubated in osteogenic
medium in the presence or absence of rhBMP-2 for up to 12
days and their ability to mineralize determined by Alizarin Red
S staining. Marked increases in mineral production in respon-
se to increasing concentrations of rhBMP-2 were observed
already after 10 days of osteoblast differentiation in osteoge-
nic medium either with dexamethasone (OM) or without
dexamethasone (OM-D) (Figure 4A). By day 12, positive stai-
ning for Alizarin Red S was evident in all cultures treated with
complete osteogenic medium (OM) (Figure 4B). By contrast,
mineral deposition in cultures incubated without dexametha-
sone (OM-D) was only evident following treatment with the
Fig. 3 Dorsopalmar radiographic views of the PIP joint of both forelimbs of Case 3. On the right side (A), an ill-defined radiolucent region
in the distal lateral condyle of P1 is visible (black arrow). On the left (E), a similar but smaller radiolucency is visible on the distal medial P1
(black arrow). The dorsal plane CT images revealed a round SCL (arrow) on the right P1 (B), and a smaller, irregular SCL (arrow) on the left P1 (F).
Both defects were debrided as shown in the dorsal radiographic views of the PIP joints 2 days after surgery, where the drill canal is visible on
the right (C) as well as on the left (G) side. At 7 months after surgery, the same radiographic views revealed progressive filling of the drill canal
and SCLs in both forelimbs (D,H, arrows).
Fig. 4 Analysis of mineralization.
Equine osteoblasts were incubated
with recombinant BMP-2 in the pre-
sence of osteogenic medium (OM) for
10 (A) and 12 (B) days and mineral
deposition visualized by Alizarin red
staining. OM, complete osteogenic
medium; OM-D, without dexametha-
sone; OM-D/BG, without dexametha-
sone and b-glycerophosphate.
A B C D
E F G H
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two highest concentrations of rhBMP-2 (Figure 4B). In all
cases, removal of b-glycerophosphate from the osteogenic
medium (OM-D/BG) prevented mineral formation, even in
the presence of rhBMP-2.
Treatment of equine osteoblasts with rhBMP-2 also led to sig-
nificant increases in ALP activity levels (Figure 5A). The grea-
test effects were observed using 50 and 100 ng/ml rhBMP-2,
with ALP activity showing the greatest increase at day 5. We
also investigated the effect of rhBMP-2 on the level of secre-
ted osteocalcin, an important mediator of mineral formation.
Comparable levels of osteocalcin were observed between all
treatment groups at day 4 after the addition of osteogenic
medium (Figure 5B). However, by day 7, osteocalcin levels
had significantly decreased in cultures treated with 50 or 100
ng/ml rhBMP-2, and remained significantly reduced through-
out the course of the study. 
We used RT-qPCR in order to assess the influence of rhBMP-2
on various genetic markers associated with osteogenesis inclu-
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ding Runt-related transcription factor 2 (RUNX-2), alkaline
phosphatase (ALP) and collagen type 1 alpha 2 chain
(COL1A2). Expression levels of RUNX2 at days 2 and 5 were
significantly increased in all treatment groups as compared to
control cells cultured in non-osteogenic medium (Figure 6A).
However, treatment with rhBMP-2 failed to significantly elevate
these levels further. By contrast, significant increases in ALP
expression levels in cells treated with 100ng/ml rhBMP-2 were
already evident by day 2 (Figure 6B). Although ALP expression
levels had significantly increased in all groups as compared to
controls by day 5, cells treated with 100ng/ml rhBMP-2 conti-
nued to express significantly greater levels of ALP than all other
groups. Expression levels of COL1A2 at day 2 were compara-
ble between treatment groups, although significantly reduced
as compared to controls (Figure 6C). By day 5, although
expression levels of COL1A2 had increased by 4-fold in con-
trol cells, expression levels remained significantly reduced in all
treatment groups. Furthermore, cells treated with 100ng/ml
rhBMP2 expressed significantly less COL1A2 as compared to
untreated cells, or cells treated with 10ng/ml rhBMP-2. 
Fig. 6 RT-qPCR analysis of osteogenic markers. Equine osteoblasts were incubated with recombinant BMP-2 (number in paren-
theses refers to the concentration used) in complete osteogenic medium (OM) for up to 5 days and RNA isolated and the expres-
sion levels of RUNX2 (A), ALP (B), and COL1A2 (C) determined by RT-qPCR at selected time points. Data was normalized to
GAPDH and expressed as fold change as compared to cells treated with OM only (value 1) using the comparative CT method.
Data is expressed as mean ± S.D., and statistical significance determined by one-way ANOVA. * P < 0.01 as compared to cells
in non-osteogenic medium (control). # P < 0.05, ## P < 0.01.
Fig. 5 Analysis of ALP activity and oste-
ocalcin expression. Equine osteoblasts were
incubated with recombinant BMP-2 in com-
plete osteogenic medium (OM) for up to 10
days and ALP activity (A) and osteo-calcin
secretion (B) measured at selected time
points. Data is expressed as mean ± S.D.,
and statistical significance determined by
one-way ANOVA. * P < 0.01 as compared
to cells treated with OM only.
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Discussion
Subchondral cystic lesions (SCLs) of the proximal interphalan-
geal (PIP) joint occur in the medial or lateral condyle of the
proximal phalanx, or close to the proximal articular surface of
the middle phalanx (Redding 2007). Various pathogenic pro-
cesses have been implicated in the occurrence of SCLs, with
trauma being the likely cause in mature horses (Sherlock and
Mair 2011) and osteochondrosis in juvenile horses (Ver-
schooten and De Moor 1982). In the cases described herein,
a developmental aetiology was suspected based on the
young age and the bilateral occurrence in two of the three
horses affected, and lack of any history of trauma (Verschoo-
ten and De Moor 1982).
Overall, the prognosis for return to performance for horses
with phalangeal SCLs ranges from 30–90%, but is largely
dependent on the age, treatment regime, location of the
SCL, and concurrent osteoarthritis (Sherlock and Mair
2011). Smith et al. (2005) have suggested that older horses,
and those with pre-existing osteoarthritis, have a significantly
poorer prognosis following surgical debridement of femoral
SCLs, with only 35% of horses older than 3 years returning
to soundness after debridement. Similarly, phalangeal SCLs
have a poorer prognosis in older horses than in younger hor-
ses (Howard et al. 1995). Conservative or surgical interven-
tions are used to treat SCLs in the PIP joint. Conservative tre-
atment consists of a rest period out at grass, followed by gra-
dual return to full training (Jeffcott and Kold 1982), or con-
trolled exercise and systemic administration of NSAIDs, often
in combination with intra-articular medication (Trotter and
Dyson 2003). However, since the outcome of conservative
treatment of SCLs is generally poor, surgical intervention is
currently the recommended treatment option (McIlwraith
2013), especially in older horses, or in horses that are
refractory to conservative treatment (Ortved et al. 2012,
Smith et al. 2005). Since SCLs of the PIP joint are not arthro-
scopically accessible, surgical debridement is usually perfor-
med through a transcortical approach (Fürst et al. 1997,
Mettenleiter 2014). In order to expedite new bone formation
within the defect sites, the use of various osteoinductive bio-
materials including calcium phosphate (Fürst et al. 1997,
Mettenleiter 2014) and PTH1-34-enriched fibrin hydrogel
(Fürst et al. 1997) have previously been investigated. Fürst et
al. (1997) demonstrated full recovery of SCLs in the distal
aspect of the proximal phalanx in 2 out of 3 foals treated
with transcortical debridement and filling of the defect with
tricalcium phosphate granules. The same group also
demonstrated complete healing of an SCL of the distal
aspect of the proximal phalanx in a filly following debride-
ment and filling of the defect with PTH1-34 enriched fibrin
hydrogel (Fürst et al. 2007). 
Recent studies have highlighted the beneficial effects of using
rhBPM-2 to repair various experimentally induced equine
bone and articular cartilage defects. Tsuzuki et al. (2012)
demonstrated that rhBMP-2/b-TCP sponges could significant-
ly enhance bone regeneration as compared to either compo-
nent alone. Moreover, significant improvements in the hea-
ling of surgically induced bone and osteochondral defects
were demonstrated following treatment with rhBMP-2/b-TCP
sponges in combination with MSCs (Seo et al. 2014), or with
MSCs and platelet rich plasma (Seo et al. 2013, Seo et al.
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2015, Tsuzuki et al. 2013). In the present study, we set out to
evaluate rhBMP-2 as an adjunct to debridement in the treat-
ment of clinical cases of SCLs in three horses. We hypothesi-
zed that, when applied locally to the SCL, rhBMP-2 would
facilitate filling of the entire cavity with new bone tissue via its
ability to stimulate osteoblast-mediated mineralization. In
order to accomplish this, debrided subchondral defects were
filled with a collagen sponge containing up to 2mg of rhBMP-
2. In all cases, treatment resulted in increased bone density,
decreased cyst size, and an absence of lameness. Therefore,
these findings support the use of rhBMP-2 as a possible new
treatment strategy for cystic lesions in the pastern joint of hor-
ses. However, further studies using larger patient cohorts and
appropriate controls (e.g. carrier alone) are clearly needed in
order to fully assess the clinical efficacy of rhBMP-2 in treating
cystic lesions in horses. Ideally, comparisons should also be
made between horses treated with rhBMP-2 and those treated
conservatively over extended periods of time.
The osteoinductive effects of rhBMP-2 are primarily mediated
through direct stimulation of osteoblasts and their precursors
(Kirker-Head 1995, Sandhu et al. 1997). Treatment of equine
subchondral cystic lesions with rhBMP-2 would therefore be
expected to influence the differentiation and mineralization of
resident BMSC-derived osteoblasts. However, although the
role of rhBMP-2 in equine BMSC osteogenesis has previously
been described (Carpenter et al. 2010, Glynn et al. 2013,
Murray et al. 2010), its influence on equine osteoblast diffe-
rentiation has up until now remained undetermined. Findings
from our in vitro studies confirmed that rhBMP-2 stimulated
equine osteoblast mineralization as evidenced by marked
increases in Alizarin Red S staining, even in the absence of
dexamethasone, and this was associated with significant
increases in the activity levels of alkaline phosphatase (ALP),
a hydrolase enzyme centrally involved in driving mineraliza-
tion (Golub and Boesze-Battaglia 2007). These findings are
in agreement with previous observations from studies exami-
ning the influence of human BMP-2 overexpression on the
osteogenic differentiation of equine BMSCs, where increases
in ALP activity and mineralization were detected in cells trans-
duced with adenovirus encoding BMP-2 (Carpenter et al.
2010, Murray et al. 2010). However, more recently it has
been suggested that osteogenic induction of equine BMSCs is
primarily dependent on dexamethasone, rather than BMP-2
(Glynn et al. 2013). It is possible that these contradictory fin-
dings may be explained by differences in the concentrations
of BMP-2 used. 
In addition to increases in mineralization and ALP activity, we
also observed significant decreases in secreted osteocalcin
levels in response to rhBMP-2. Osteocalcin is well recogni-
zed as an inhibitor of hydroxyapatite formation in vitro
(Hauschka and Wians 1989, Hunter et al. 1996), and its
ablation in vivo results in increased bone formation (Ducy et
al. 1996). Therefore, the ability of rhBMP-2 to enhance equi-
ne osteoblast mineralization may be directly linked to its inhi-
bitory effects on osteocalcin production. The effects of
rhBMP-2 on equine osteoblast differentiation were also eva-
luated by RT-qPCR analysis of various osteogenic markers
including ALP, COL1A2, and RUNX2. Expression levels ALP,
which encodes alkaline phosphates, were significantly incre-
ased in equine osteoblast cultures in response to osteogenic
medium at day 5. In accordance with its stimulatory effects
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on ALP protein activity, treatment with 100mg/ml rhBMP-2
induced a significant increase in ALP expression as compa-
red to all other treatment groups. Expression levels of the
gene encoding collage type I alpha 2 chain, COL1A2, were
significantly reduced in equine osteoblasts in a time depen-
dent manner in response to osteogenic medium, thereby
suggesting that reductions in COL1A2 expression favoured
osteoblast maturation. This concept is supported by the fact
that treatment with 100mg/ml rhBMP-2 could further signifi-
cantly reduce COL1A2 expression in equine osteoblasts at
day 5. RUNX2 encodes the Runt-related transcription factor
2, whose primary role is to direct BMSCs towards the oste-
oblast lineage, and is subsequently downregulated during
osteoblast maturation (Komori 2010). Although we observed
significant increases in RUNX2 expression levels in equine
osteoblasts incubated in osteogenic medium as compared to
controls at both day 2 and 5, treatment with rhBMP-2 failed
to induce any significant changes in RUNX2 expression at
either time point. 
Conclusions
Treatment of equine SCLs with a combination of debridement
and filling with rhBMP-2 in collagen sponges is well tolerated
and may be favourable with regards to new subchondral
bone formation and improved lameness. Further studies with
a larger number of patients and appropriate control groups,
may therefore be warranted in order to substantiate these fin-
dings and to determine whether rhBMP-2 could be used to
treat SCLs at other anatomical locations. The ability of
rhBMP-2 to stimulate equine osteoblast differentiation in vitro
further highlights its potential use as an osteoinductive agent
in horses, and sets the stage for more in-depth investigations
into the mechanisms regulating BMP-2-induced equine oste-
oblast differentiation and mineralization. 
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